POSSIBILITIES OF HORMONAL THERAPY FOR FEMALE UROGENITAL ATROPHY


如何引用文章

全文:

开放存取 开放存取
受限制的访问 ##reader.subscriptionAccessGranted##
受限制的访问 订阅或者付费存取

详细

Objective: to study the efficacy of a lower-dose topical estradiol-containing agent (ovestin) in patients with urogenital atrophy on the basis of objective criteria. Subjects and methods. The study included 120 postmenopausal patients with symptoms of vaginal atrophy. Group 1 patients (n=60) were given the topical dosage form of hormonal replacement therapy — intravaginal ovestin cream in the standard therapeutic dosage of 0.5 mg once daily every day. In Group 2 patients (n=60), ovestin cream was intravaginally applied in a dosage of 0.5 mg once daily on alternate days. The course of therapy was 3 months. The studies comprised determination of the pH of the vaginal contents and the value of vaginal epithelial maturity; colposcopy; a comprehensive microbiological study of vaginal discharge; and a 5-point Barlow scale to estimate the intensity of symptoms of vaginal atrophy. Results. The use of an estradiol topical formulation (ovestin cream) in the standard therapeutic dose and its double reduction was equally effective in patients with urogenital atrophy, as confirmed by a number of objective criteria and allows prevention of possible adverse events.

全文:

受限制的访问

作者简介

V. BALAN

Academician V.I. Kulakov Research Center of Obstetrics, Gynecology, and Perinatology, Ministry of Health and Social Development of Russia

Email: vbalan@freemail.ru

L. KOVALEVA

Academician V.I. Kulakov Research Center of Obstetrics, Gynecology, and Perinatology, Ministry of Health and Social Development of Russia; I.M. Sechenov First Moscow State Medical University

Zh. AMIROVA

Academician V.I. Kulakov Research Center of Obstetrics, Gynecology, and Perinatology, Ministry of Health and Social Development of Russia

I. RAFAELYAN

Academician V.I. Kulakov Research Center of Obstetrics, Gynecology, and Perinatology, Ministry of Health and Social Development of Russia

参考

  1. Балан В.Е., Сметник В.П., Анкирская А.С. и др. Урогенитальные расстройства в климактерии //Медицина климактерия / Под ред. В.П. Сметник. - М.: Литера, 2006. — С. 217-290.
  2. Al-Baghdadi O., Ewies A.A. Topical estrogen therapy in the management of postmenopausal vaginal atrophy: an up-to-date overview // Climacteric. -2009. - Vol. 12. - P. 91-105.
  3. Barlow D.H., Cardozo L.D., Francis R.M. et al. Urogenital ageing and its effect on sexual health in older British women // Br. J. Obstet. Gynaecol. - 1997. - Vol. 104. - P. 87-91.
  4. Calleja-Agius J., Brincat M.P. Urogenital atrophy // Climacteric. - 2009. - Vol. 12. - P. 279-285.
  5. Cavallini A., Dinaro E., Giocolano A. et al. Estrogen receptor (ER) and ER-related receptor expressoin in normal and atrophic human vagina // Maturitas. - 2008. - Vol. 59, № 3. - P. 219-225.
  6. Estrogen and progestogen use in postmenopausal women: position statement of The North American Menopause Society // J. N. Am. Menopause Soc. - 2008. - Vol. 15, № 4. -P. 584-603.
  7. Gebhardt J., Richard D., Barrett T. Expression of estrogen receptor isoforms alpha and beta messenger RNA in vaginal tissue of premenopausal and postmenopausal women // Am. J. Obstet. Gynecol. - 2001. - Vol. 185. - P. 1325-1330.
  8. Johnston S.L., Farrell S.A., Bouchard C. et al. The detection and management of vaginal atrophy // J. Obstet. Gynaecol. Can. - 2004. - Vol. 26. - P. 503-515.
  9. Practical recommendations for hormone replacement therapy in the peri- and postmenopause // Climacteric. - 2004. -Vol. 7. - P. 210-216.
  10. Raghunandan C., Agrawal S., Dubey P. et al. A comparative study of the effects of local estrogen with or without local testosterone on vulvovaginal and sexual dysfunction in postmenopausal women // J. Sex. Med. - 2010. - Vol. 7. - P. 1284-1290.
  11. Weisberg E., Ayton R., Darling G. et al. Endometrial and vaginal effects of low-dose estradiol delivered by vaginal ring or vaginal tablet // Climacteric. - 2005. - Vol. 8. - P. 83-92.

补充文件

附件文件
动作
1. JATS XML
下载
##common.cookie##